Now Reading: Indian scientists develop smart cancer drug RK-251 as chemo alternative
-
01
Indian scientists develop smart cancer drug RK-251 as chemo alternative
Indian scientists develop smart cancer drug RK-251 as chemo alternative
Researchers from the Institute of Advanced Study in Science and Technology (IASST) and IIT Guwahati have developed RK-251, a smart cancer drug candidate that activates selectively inside cancer cells, potentially offering a…
Researchers from the Institute of Advanced Study in Science and Technology (IASST) and IIT Guwahati have developed RK-251, a smart cancer drug candidate that activates selectively inside cancer cells, potentially offering a targeted alternative to conventional chemotherapy. The drug is designed as an inactive prodrug that becomes active in the high reactive oxygen species (ROS) environment typical of cancer cells, releasing the potent anti-cancer compound NBDHEX.
In preclinical studies, RK-251 showed strong efficacy against aggressive triple-negative breast cancer cell lines with significantly lower toxicity to healthy cells. Safety tests on zebrafish embryos found no observable toxic effects and confirmed the expected ROS-triggered fluorescence. ThePrint notes the drug also carries a fluorescent molecule QCy7 for a theranostic approach combining therapy and diagnostics.
The study was published in the ACS Journal of Medicinal Chemistry. Researchers stress that further extensive preclinical testing is required before the compound can advance to human clinical trials.
Indian Opinion Analysis
Both Mathrubhumi and ThePrint report the development as straight science news with neutral framing, focusing on the drug's mechanism and preclinical results. Mathrubhumi leads with the headline framing of replacing chemotherapy, while ThePrint emphasises the drug's design for aggressive breast cancer and includes detailed explanation of the GSTP1 enzyme mechanism. Neither source offers any criticism or political angle. The measured takeaway is that while RK-251 represents promising preclinical research, it remains years away from clinical use, pending further safety and efficacy testing.
Coverage: 2 sources, 2 neutral
Sources (2): english.mathrubhumi.com (neutral report), theprint.in (neutral report)
This story was synthesised by AI from the 2 sources linked above.
Updated: this story now draws on 2 sources.
